Eric Nuermberger

PROFESSOR

19992019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 20 Similar Profiles
Tuberculosis Medicine & Life Sciences
rifapentine Medicine & Life Sciences
Pyrazinamide Medicine & Life Sciences
Rifampin Medicine & Life Sciences
Mycobacterium tuberculosis Medicine & Life Sciences
Multidrug-Resistant Tuberculosis Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Linezolid Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2019

High-dose rifamycins enable shorter oral treatment in a murine model of mycobacterium ulcerans disease

Omansen, T. F., Almeida, D., Converse, P. J., Li, S. Y., Lee, J., Stienstra, Y., van der Werf, T., Grosset, J. H. & Nuermberger, E., Feb 1 2019, In : Antimicrobial agents and chemotherapy. 63, 2, e01478-18.

Research output: Contribution to journalArticle

rifapentine
Rifamycins
Mycobacterium ulcerans
Rifampin
Buruli Ulcer

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis

Leung-Theung-Long, S., Coupet, C. A., Gouanvic, M., Schmitt, D., Ray, A., Hoffmann, C., Schultz, H., Tyagi, S., Soni, H., Converse, P. J., Arias, L., Kleinpeter, P., Sansas, B., Mdluli, K., Vilaplana, C., Cardona, P. J., Nuermberger, E., Marchand, J. B., Silvestre, N. & Inchauspé, G., May 1 2018, In : PLoS One. 13, 5, e0196815.

Research output: Contribution to journalArticle

Vaccinia
Chemotherapy
Vaccinium
Mycobacterium tuberculosis
Combination Drug Therapy

Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis

Ammerman, N., Swanson, R. V., Bautista, E. M., Almeida, D. V., Saini, V., Omansen, T. F., Guo, H., Chang, Y. S., Li, S. Y., Tapley, A., Tasneen, R., Tyagi, S., Betoudji, F., Moodley, C., Ngcobo, B., Pillay, L., Bester, L. A., Singh, S. D., Chaisson, R. E., Nuermberger, E. & 1 othersGrosset, J. H., Jul 1 2018, In : Antimicrobial Agents and Chemotherapy. 62, 7, e00636-18.

Research output: Contribution to journalArticle

Clofazimine
Tuberculosis
Pharmaceutical Preparations
Therapeutics
Multidrug-Resistant Tuberculosis

Long-acting formulations for the treatment of latent tuberculous infection: Opportunities and challenges

Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., Nuermberger, E., Kim, P., Barry, C. E., Owen, A., Hazuda, D. & Flexner, C. W., Feb 1 2018, In : International Journal of Tuberculosis and Lung Disease. 22, 2, p. 125-132 8 p.

Research output: Contribution to journalReview article

Tuberculosis
Infection
HIV
Drug Compounding
Virus Diseases

Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis

Deshpande, D., Srivastava, S., Nuermberger, E., Koeuth, T., Martin, K. R., Cirrincione, K. N., Lee, P. S. & Gumbo, T., Nov 28 2018, In : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 67, 3, p. S342-S348

Research output: Contribution to journalArticle

Linezolid
Tuberculosis
Mitochondrial Genes
Stem Cells
Therapeutics